Application of Esketamine combined with Ropivacaine in brachial plexus block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071534

Enrollment

Unknown

Registered

2023-05-17

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical anesthesia

Interventions

group 1:0.4% Ropivacaine +0.5mg/kg esketamine

group 2:0.4% Ropivacaine +0.1mg/kg esketamine

group 3:0.4% ropivacaine plus the same amount of saline

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients undergoing upper extremity operation; There is no gender limitation; Age 18-60 years old; BMI 18.5-23.9kg/m2; ASA Class I or II

Exclusion criteria

Exclusion criteria: History of severe cardiovascular and cerebrovascular diseases; Mental illness and cognitive dysfunction can not cooperate; A history of opioid abuse; Local anesthetic allergy; There is contraindication of nerve block anesthesia;

Design outcomes

Primary

Measure	Time frame
Duration of sensory nerve block;	—

Secondary

Measure	Time frame
Duration of motor nerve block;SDS score;	—

Countries

China

Contacts

Public ContactMin Zheng

Shiyan People's Hospital, Hubei Province

lhj1286@163.com+86 138 7276 7699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026